LS411N Xenograft Model Service for Colon Cancer

The LS411N xenograft model offers a robust preclinical platform for evaluating therapeutic strategies against colon cancer, leveraging a well-characterized cell line with distinct molecular features including BRAF V600E mutation and microsatellite instability. At Alfa Cytology, we specialize in delivering validated LS411N xenograft models with rigorous quality control and comprehensive endpoint analysis to accelerate your colon cancer drug development pipeline.

Overview of LS411N Xenograft Model for Colon Cancer

The LS411N cell line was established in 1985 from a primary tumor biopsy of a Dukes' type B, poorly differentiated cecal carcinoma in a 32-year-old male patient. As a metastatic human colon carcinoma cell line, LS411N has been extensively utilized in preclinical oncology research, particularly for studying BRAF-mutant colorectal cancers and evaluating targeted therapeutic interventions. The cell line exhibits epithelial morphology, expresses carcinoembryonic antigen (CEA), and demonstrates tumorigenic potential in immunodeficient mice, making it an excellent candidate for xenograft model development.

LS411N carries a homozygous BRAF V600E mutation, which is present in approximately 10% of colorectal cancers and is associated with distinct clinical and molecular features. Additionally, the cell line harbors mutations in APC and TP53 genes, displays microsatellite instability (MSI) status, and exhibits a high mutation count. These molecular characteristics make LS411N particularly valuable for investigating targeted therapies such as BRAF inhibitors, combination regimens with anti-EGFR antibodies, and studies exploring chemoresistance mechanisms including 5-fluorouracil resistance linked to CD133-positive cancer stem cell populations.

Figure 1. Ruxolitinib induces apoptosis in human colorectal cancer cells. (Li, Xia, et al., 2021)

Cell Line Information: LS411N

The LS411N cell line is a well-characterized human colorectal carcinoma cell line with the following detailed specifications:

Our Services

Alfa Cytology provides comprehensive LS411N xenograft model services tailored to your preclinical research needs, from model establishment and in vivo validation to pharmacodynamic and pharmacokinetic studies, ensuring high-quality data to support your colon cancer therapeutic development programs.

Workflow of LS411N Xenograft Model Construction

The construction of LS411N xenograft models follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable data generation for preclinical therapeutic evaluation. Each step is carefully monitored to maintain model integrity and experimental consistency.

1. Cell Culture and Expansion: LS411N cells are cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum under standard conditions (37 degrees C, 5% CO2). Cells are expanded to the required quantity and verified for mycoplasma negativity, viability, and authentication prior to inoculation.
2. Cell Preparation for Injection: Cultured cells are harvested during the logarithmic growth phase, washed with sterile PBS, and resuspended in a suitable carrier matrix such as Matrigel or serum-free medium. Cell viability is confirmed by trypan blue exclusion, and cell concentration is adjusted based on the specific study requirements.
3. Animal Preparation and Cell Inoculation: Immunodeficient mice (typically nude or NOD-SCID) are acclimatized under pathogen-free conditions. LS411N cells are injected subcutaneously into the flank or orthotopically into the cecal wall, depending on the study design. Injection volumes and cell numbers are standardized to ensure consistent tumor take rates.
4. Tumor Monitoring and Growth Assessment: Tumor development is monitored by palpation and caliper measurement beginning approximately 7-10 days post-inoculation. Tumor volume is calculated using the formula (length x width^2) / 2. Mice are randomized into treatment groups once tumors reach the predetermined volume (typically 100-150 mm^3).
5. Endpoint Analysis and Sample Collection: At study completion, tumors are excised, weighed, and processed for downstream analyses including histopathology, immunohistochemistry, biomarker profiling, and molecular characterization. Blood and tissue samples are collected for pharmacokinetic and pharmacodynamic assessments.

Figure 2: Schematic workflow illustrating the derivation and construction of the LS411N Xenograft Model at Alfa Cytology.

Case Study-LS411N Xenograft Model Development

In a representative preclinical study, the LS411N xenograft model was successfully established with consistent tumor take rates and predictable growth kinetics. The model demonstrated robust responsiveness to standard-of-care chemotherapeutic agents and provided a reliable platform for evaluating novel targeted therapies. Detailed tumor growth curves, survival data, and biomarker analysis results are available upon request for researchers interested in leveraging this model for their drug development programs.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering high-quality, reproducible LS411N xenograft models that meet the stringent demands of preclinical oncology research. Our integrated service platform combines technical expertise with rigorous quality assurance to accelerate your therapeutic development timeline.

• Extensive experience in establishing and validating LS411N xenograft models with documented tumor take rates and growth kinetics.
• Comprehensive molecular characterization of models including BRAF V600E mutation confirmation and MSI status verification.
• Flexible study designs accommodating subcutaneous, orthotopic, and metastatic model configurations tailored to specific research questions.
• Integrated pharmacodynamic and pharmacokinetic analysis capabilities to support comprehensive preclinical efficacy assessments.
• Strict adherence to animal welfare guidelines and regulatory compliance standards in all preclinical research operations.
• Dedicated project management ensuring transparent communication, timely reporting, and seamless integration with your research workflow.

Contact Us

Ready to advance your colon cancer research with our LS411N xenograft model services? Contact us today to discuss your project requirements and receive a customized proposal tailored to your preclinical objectives. Our scientific team is available to address your technical questions and guide you through every stage of your study.

Reach out to us now to explore how Alfa Cytology's LS411N xenograft model platform can accelerate your therapeutic development pipeline and deliver the reliable preclinical data you need.

For research use only. Not intended for any clinical use.